Literature DB >> 22948709

Adenosine transport blockade restores attenuated cardioprotective effects of adenosine preconditioning in the isolated diabetic rat heart: potential crosstalk with opioid receptors.

Nidhi Krishan Sharma1, Nanjaian Mahadevan, Pitchai Balakumar.   

Abstract

Considering the reduced ability of cardiac fibroblasts to release adenosine and increased ability of interstitial adenosine uptake during diabetes mellitus, the present study investigated the effect of adenosine preconditioning and the existence of cross-talk with opioid receptor activation in the diabetic rat heart subjected to ischemia-reperfusion (I/R). Langendorff-perfused normal and streptozotocin (65 mg/kg, i.p., once)-administered diabetic (after 8-weeks) rat hearts were subjected to 30-min global ischemia and 120-min reperfusion. Myocardial infarct size using triphenyltetrazolium chloride staining, markers of cardiac injury such as lactate dehydrogenase (LDH) and creatine kinase (CK-MB) release, coronary flow rate (CFR) and myocardial oxidative stress were assessed. The diabetic rat heart showed high degree of I/R injury with increased LDH and CK-MB release, high oxidative stress and reduced CFR as compared to the normal rat heart. The adenosine preconditioning (10 μM) afforded cardioprotection against I/R injury in the normal rat heart that was prevented by naloxone (100 μM) pre-treatment. Conversely, adenosine preconditioning-induced cardioprotection was abolished in the diabetic rat heart. However, co-administration of dipyridamole (100 μM), adenosine reuptake inhibitor, markedly restored the cardioprotective effect of adenosine preconditioning in the diabetic rat heart, and this effect was also abolished by naloxone pre-treatment. The reduced myocardial availability of extracellular adenosine might explain the inability of adenosine preconditioning to protect the diabetic myocardium. The pharmacological elevation of extracellular adenosine restores adenosine preconditioning-mediated cardioprotection in the diabetic myocardium by possibly involving opioid receptor activation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22948709     DOI: 10.1007/s12012-012-9182-y

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  10 in total

1.  Elevated Expression of Carboxy-Terminal Modulator Protein (CTMP) Aggravates Brain Ischemic Injury in Diabetic db/db Mice.

Authors:  Yu Chen; Min Cai; Jiao Deng; Li Tian; Shiquan Wang; Li Tong; Hailong Dong; Lize Xiong
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

Review 2.  Mitochondria as a target of cardioprotection in models of preconditioning.

Authors:  Magdaléna Jašová; Ivana Kancirová; Iveta Waczulíková; Miroslav Ferko
Journal:  J Bioenerg Biomembr       Date:  2017-07-20       Impact factor: 2.945

3.  Effect of zinc supplements in the attenuated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart.

Authors:  Sunil Kumar Kansal; Uma Jyoti; Samridhi Sharma; Arun Kaura; Rahul Deshmukh; Sandeep Goyal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-03-07       Impact factor: 3.000

Review 4.  Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart.

Authors:  John P Headrick; Louise E See Hoe; Eugene F Du Toit; Jason N Peart
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

5.  Fenofibrate attenuates impaired ischemic preconditioning-mediated cardioprotection in the fructose-fed hypertriglyceridemic rat heart.

Authors:  Lalita Babbar; Nanjaian Mahadevan; Pitchai Balakumar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-01-17       Impact factor: 3.000

6.  Polyunsaturated fatty acid induces cardioprotection against ischemia-reperfusion through the inhibition of NF-kappaB and induction of Nrf2.

Authors:  Jorge G Farías; Catalina Carrasco-Pozo; Rodrigo Carrasco Loza; Néstor Sepúlveda; Pedro Álvarez; Mauricio Quezada; John Quiñones; Víctor Molina; Rodrigo L Castillo
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

Review 7.  Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Authors:  Lars Petter Jordheim; David Durantel; Fabien Zoulim; Charles Dumontet
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

Review 8.  Experimental Diabetes Mellitus in Different Animal Models.

Authors:  Amin Al-Awar; Krisztina Kupai; Médea Veszelka; Gergő Szűcs; Zouhair Attieh; Zsolt Murlasits; Szilvia Török; Anikó Pósa; Csaba Varga
Journal:  J Diabetes Res       Date:  2016-08-09       Impact factor: 4.011

Review 9.  Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection.

Authors:  Jake Russell; Eugene F Du Toit; Jason N Peart; Hemal H Patel; John P Headrick
Journal:  Cardiovasc Diabetol       Date:  2017-12-04       Impact factor: 9.951

Review 10.  Mechanisms involved in adenosine pharmacological preconditioning-induced cardioprotection.

Authors:  Lovedeep Singh; Ritu Kulshrestha; Nirmal Singh; Amteshwar Singh Jaggi
Journal:  Korean J Physiol Pharmacol       Date:  2018-04-25       Impact factor: 2.016

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.